We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Nanofluidic Device Traps and Concentrates Pathogenic Bacteria

By LabMedica International staff writers
Posted on 31 Mar 2020
Print article
Image: The image shows bacterial cells trapped in a three-dimensional microbead matrix (Photo courtesy of Wenrong He, Rochester Institute of Technology)
Image: The image shows bacterial cells trapped in a three-dimensional microbead matrix (Photo courtesy of Wenrong He, Rochester Institute of Technology)
A nanofluidic device containing stacked magnetic beads of different sizes has been developed to efficiently trap, concentrate, and retrieve Escherichia coli (E. coli) bacteria from liquid suspensions.

The miniaturized, inexpensive, and transparent device developed by investigators at Rutgers University (Rochester, NY, USA) and the Rochester Institute of Technology (NY, USA) is easy to fabricate and operate, making it ideal for pathogen separation in both laboratory and point-of-care settings.

The investigators used computational fluid dynamics, three-dimensional tomography technology, and machine learning to probe and explain the effects of bead stacking in a small three-dimensional space with various flow rates. Ultimately, a combination of beads with different sizes was utilized to achieve a high capture efficiency (approximately 86%) with a flow rate of 50 microliters per minute.

In addition, the investigators showed that the high deformability of the device enabled retrieval of an E. coli sample from a bacterial suspension by applying a higher flow rate followed by rapid magnetic separation. This unique function was also utilized to concentrate E. coli cells from the original bacterial suspension. An on-chip concentration factor of about 11 times was achieved by inputting 1300 microliters of the E. coli sample and then concentrating it down to 100 microliters.

The new device is expected to play an important role in the identification and isolation of drug resistant strains of bacteria, from which at least 700,000 people die each year, including 230,000 deaths from multidrug-resistant tuberculosis.

"The rapid identification of drug-resistant bacteria allows health care providers to prescribe the right drugs, boosting the chances of survival," said contributing author Dr. Ruo-Qian (Roger) Wang, assistant professor of civil and environmental engineering at Rutgers University.

The nanofluidic device was described in the February 19, 2020, issue of the journal ACS Applied Materials & Interfaces.

Related Links:
Rutgers University
Rochester Institute of Technology


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more